Keyphrases
Past-present
100%
Epoetin Alfa
100%
Futures Past
100%
Pure Red Cell Aplasia
100%
Eprex
36%
Erythropoietin
27%
Regulatory Agencies
18%
Europe
18%
Etiology
18%
Canada
18%
Australia
18%
Antibody-mediated
18%
Human Serum Albumin
18%
Hemodialysis Patients
18%
Darbepoetin Alfa
18%
Academic Researchers
9%
Anemia
9%
Route of Administration
9%
Asia
9%
Academicians
9%
Paris
9%
Hemodialysis
9%
Singapore
9%
Administration Safety
9%
Subcutaneous Administration
9%
Antibody-associated
9%
Rubber Stopper
9%
Safety Database
9%
Infrequent Classes
9%
Prefilled Syringe
9%
Teflon Coating
9%
Exposure-adjusted Incidence Rate
9%
Pharmacology, Toxicology and Pharmaceutical Science
Recombinant Erythropoietin
100%
Pure Red Cell Anemia
100%
Hemodialysis
25%
Erythropoietin
25%
Human Serum Albumin
16%
Toxicity Class
8%
Politef
8%
Anemia
8%
Subcutaneous Injection
8%